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Abstract
Background: The US Surgeon General’s Report on Bone Health suggests America’s bone-health is in jeopardy and
issued a “call to action” to develop bone-health plans that: (1) improve nutrition, (2) increase health literacy and, (3)
increase physical activity. This study is a response to this call to action.
Methods: After signing an informed consent, 158 adults agreed to follow an open-label bone-health plan for six
months after taking a DXA test of bone density, a 43-chemistry blood test panel and a quality of life inventory
(AlgaeCal 1). Two weeks after the last subject completed, a second group of 58 was enrolled and followed the
identical plan, but with a different bone-health supplement (AlgaeCal 2).
Results: There were no significant differences between the two groups in baseline bone mineral density (BMD) or
in variables related to BMD (age, sex, weight, percent body fat, fat mass, or fat-free mass). In both groups, no
significant differences in BMD or related variables were found between volunteers and non-volunteers or between
those who completed per protocol and those who were lost to attrition.
Both groups experienced a significant positive mean annualized percent change (MAPC) in BMD compared to
expectation [AlgaeCal 1: 1.15%, p = 0.001; AlgaeCal 2: 2.79%, p = 0.001]. Both groups experienced a positive MAPC
compared to baseline, but only AlgaeCal 2 experienced a significant change [AlgaeCal 1: 0.48%, p = 0.14; AlgaeCal
2: 2.18%, p < 0.001]. The MAPC in AlgaeCal 2 was significantly greater than that in AlgaeCal 1 (p = 0.005). The
MAPC contrast between compliant and partially compliant subjects was significant for both plans (p = 0.001 and p
= 0.003 respectively). No clinically significant changes in a 43-panel blood chemistry test were found nor were
there any changes in self-reported quality of life in either group.
Conclusions: Following The Plan for six months with either version of the bone health supplement was associated
with significant increases in BMD as compared to expected and, in AlgaeCal 2, the increase from baseline was
significantly greater than the increase from baseline in AlgaeCal 1. Increased compliance was associated with
greater increases in BMD in both groups. No adverse effects were reported in either group.
Trial Registration: ClinicalTrials.gov NCT01114685
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In its 2004-2009 Strategic Plan [1] NIH’s Office of Diet-
ary Supplements seeks to stimulate research assessing
the effects of dietary supplements on biomarkers asso-
ciated with chronic diseases, optimal health and
improved performance. One important biomarker meet-
i n gt h i sg o a li sB M D ,o f t e nv i e w e da st h e“gold stan-
dard” for assessing bone health. In the same year (2004),
the Surgeon General’s Report on Bone Health [2]
reported that by 2020 half of all American citizens older
than 50 will be at risk for fractures, and that there is a
bone health crisis in America due to increasingly seden-
tary lifestyles, absence of current information about
bone health, and inadequate nutrition. The Surgeon
General (SG) recommended that people of all ages
ensure they are getting the recommended amounts of
calcium and vitamin D and that supplementation may
be helpful. Pointing out that people are never too young
or too old to improve their bone health, the SG issued a
“call to action” for the development of bone health pro-
grams incorporating three components: (1) improved
nutrition, (2) improved health literacy, and (3) increased
physical activity,.
More recently, the current emphasis on CER studies
suggests they may provide an important methodology
for responding to the SG’s call to action. As defined by
The American College of Physicians, CER is the evalua-
tion of the relative clinical effectiveness, safety, and cost
of two or more medical services, drugs, devices, thera-
pies, or procedures used to treat the same condition [3].
CER studies not only compare different drugs, but
healthcare plans that include lifestyle modifications such
as diet and physical activity, and complementary and
alternative therapies that are often initiated without phy-
sician input [4]. CER is a marked departure from the
past research models that have focused on demonstrat-
ing superiority over placebos, instead of comparing the
relative efficacy and safety of new therapeutic interven-
tions [5]. This has often has led to approval of a number
of “me too” interventions that ultimately rely on a com-
pany’s marketing skills as opposed to demonstration of
superior safety and efficacy. Publication of the results of
CER studies will also require a paradigm shift in the
scientific community where, traditionally, the use of pla-
cebo or control groups in studies significantly increases
the chances for publication [6].
The purpose of this CER study was to compare
changes in BMD in two bone health plans with each
other and with age- and gender-adjusted expected
changes.
Methods
The study was approved by RCRC Institutional Review
Board http://www.RCRCIRB.com, Austin, TX, Protocol
number 1252006. It was funded by a small nutritional
company with a limited budget that initially sought to
examine the safety and efficacy of a bone-health plan
using an open-label protocol under “real world” condi-
tions approximating those in which consumers were
likely to follow either Plan. Additionally, advising sub-
jects that they had a 50-50 chance of receiving an inac-
tive placebo for six months was thought to increase the
difficulty in recruiting subjects, particularly highly moti-
vated subjects who were seeking to improve their bone
health, thus creating volunteer biases. The decision was
also influenced by a desire to use available funds to
increase the number of subjects in the treatment group
in order to examine volunteer bias and conduct sub-
group compliance analyses.
During the study, new information became available
suggesting that The Plan might be enhanced by making
changes in the nutritional composition of the bone-
health supplement. Upon receipt of the ending data, a
second study was commissioned to retain the physical
activity and health literacy component, but to alter the
bone-health supplement with different kinds and
amounts of some of the bone-health ingredients.
The Bone-Health Plans
To provide the improved nutrition component of the
SG’s recommendations, the two groups were provided
with the bone-health supplements shown in Table 1.
Both formulas were analyzed by Exova Labs, Chicago, IL
for confirmation of nutrient levels and lack of heavy
minerals and other contaminating ingredients. Calcium,
magnesium and other minerals were validated by
Advanced Labs, Salt Lake City, UT. AlgaeCal (AC) is a
plant-sourced form of calcium made by milling whole,
live-harvested sea algae found on the South American
Table 1 Components of two versions of the bone-health
plan provided to subjects in Grp 1 and Grp 2
Ingredient or Component Grp 1 Grp 2
Pedometer-based activity program Yes Yes
Health Literacy Information Yes Yes
Strontium Citrate (mg) 680 680
AlgaeCal Bone-health Supplement 2,400 2,520
Trace Minerals in AlgaeCal (mg) 1,608 1,688
Calcium (mg) 720 756
Magnesium (mg)* 72 75
Magnesium from magnesium carbonate (mg) 0 275
Vitamin D-3 (IUs of Cholecalciferol) 800 1,600
Vitamin K-2 as MK-4 (mg) 1.5 0
Vitamin K-7 as MK-7 (mcg) 0 100
Boron (mg) 0 3
Vitamin C (mg) 0 50
*72 mg naturally occurring plus magnesium carbonate.
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other minerals known to play a role in bone health,
including magnesium, boron, silica, manganese, copper,
vanadium and strontium. A recent in vitro study
demonstrated superiority over the two most commonly
used calcium salts, calcium carbonate and calcium
citrate. Cultured human osteoblast cells (hFOB 1.19)
were treated with either AC, calcium carbonate or cal-
cium citrate. Alkaline phosphatase activity was signifi-
cantly increased with AC treatment when compared to
control, calcium carbonate or calcium citrate (4.0, 2.0
and 2.5-fold, respectively). Proliferating cell nuclear anti-
gen expression (immunocytochemical analysis), DNA
synthesis (4.0, 3.0 and 4.0 fold, respectively) and Ca2+
deposition (2.0, 1.0 and 4.0 fold, respectively) were sig-
nificantly increased in AC treated cells when compared
with control, calcium carbonate, or calcium citrate treat-
ment. AC treatment significantly reduced the H2O2-
induced oxidative stress when compared to calcium car-
bonate or calcium citrate (1.5, 1.4 fold, respectively).
This earlier study demonstrated that AC exhibited
unique properties compared to calcium carbonate or
calcium citrate on a cellular level which suggests the
need for human intervention studies such as the present
study [7]. Furthermore, safety and toxicological investi-
gations were conducted using AC and demonstrated its
broad spectrum safety [8].
To provide a health literacy component, with permis-
sion from the author, subjects were provided with rep-
rints from Chapters 5, 8, 9 & 10 of a previously
published book [9]. These chapters provided informa-
tion on bone density, and on the pedometer-based phy-
sical activity program. Calorie estimation charts and
glycemic load tables of over 300 common foods
designed to increase the quality of carbohydrate intakes
were also included [9].
To increase physical activity levels, subjects were
asked to wear a pedometer during their waking hours
and to record and track their daily activity levels using
the charts and graphs provided in their health literacy
booklet. They were also asked to follow the instructions
for personalizing the pedometer program to their perso-
nal goal weight and stride length. In addition to the
potential benefit for bone health, two reviews have sug-
gested that the use of pedometers can lead to increased
physical activity levels and significant health benefits
[10,11]. The Digi-Walker pedometer (HealthTech Pro-
ducts, LLC, San Antonio, TX) used in this study is gen-
erally considered among the most reliable and valid of
pedometers available [12].
Subjects
As shown in Figure 1, a total of 274 adults aged 18-85
were contacted from the investigators’ DXA database
and from participants in a local health fair and were
invited to complete a bone density test and to have the
study explained to them prior to enrolling (AC-1). Of
these 274 potential subjects, 158 agreed to participate
and certified that they had reviewed the Informed Con-
sent with their personal healthcare provider or physician
and that they had no medical conditions that would pre-
clude their participation. However, pregnant and lactat-
ing women were excluded irrespective of this
certification. Subjects were asked to refrain from taking
other bone-health supplements during the study. Of
these 158 adults, 125 ultimately completed the study PP,
which included providing weekly tracking data to Inte-
grative Health Technologies’ research center in San
Antonio, TX
Upon completion of the study in which subjects used
AlgaeCal 1, (AC-1) a second group, AlgaeCal 2 (AC-2)
of 80 adults followed the identical pre-enrollment proce-
dure as AC-1. Again, subjects and research technicians
were blinded with regard to the subjects’ baseline test
results. Of this total, 58 agreed to participate, 51 of
whom ultimately completed the study PP. Although
subjects in this second group followed the same Plan,
they took the revised version of the bone health supple-
ment shown in Table 1.
      
Group 1 Completed Baseline BMD Measurement  
N = 274 
Dropped   N = 33 
Non-Volunteers  N=22 
Group 1 Volunteers   N = 158  
Non-Volunteers N=116 
Group 1 Completed Per Protocol 
 N = 125 
Dropped   N = 7 
Group 2 Completed Baseline BMD Screening  
N = 80 
Group 2 Volunteers N = 58
Group 2 Completed Per Protocol 
 N = 51 
Figure 1 Flow of participants through the trial for both study
groups.
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cal conditions for both groups in order to permit a
comparison of the effects on mean BMD of the two ver-
sions of the bone health supplement. To encourage can-
did reporting for acquiring dose-related and compliance
comparisons, subjects in both groups were paid a
“reporting fee” of $2.00/day for providing daily reports
of supplement usage and side effects. Throughout the
study, subjects were repeatedly reminded that this fee
was not an “incentive” for taking the product, but rather
was for the purpose of obtaining candid information on
the effects of different levels of adherence to the bone-
health plan. Payment of the fee was contingent upon
reporting tracking information weekly and completing
the ending tests. Thus, compliance was used as an addi-
tional measure of efficacy on the assumption that if The
Plan was efficacious, compliant subjects would outper-
form partially compliant subjects.
Outcome Measures
To assess efficacy, changes in BMD were measured at
baseline and six months from baseline using dual-energy
X-ray absorptiometry (DXA) total body scans (GE Lunar
Prodigy, LUNAR Corporation, Madison, WI, USA).
Longitudinal precision was monitored for all measure-
ments using the same bone density phantom provided
by the manufacturer. To compare changes in mean
BMD over different study periods, data were converted
to MAPC. For calculation of expected changes, we used
age- and gender-adjusted norms from: GE Lunar, our
database of over 26,000 total body measurements, and
data from the National Osteoporosis Foundation [13].
We used an expected change for women under 40 yrs
of +0.1%, for 41-55, -0.5%/yr, 56 and older, -1.0%/yr and
used half these amounts for males. This may be a some-
what conservative estimate in view of population-based
longitudinal studies suggesting that, starting at age 40,
there is minor, but significant, annual bone loss [14]
that increases to 0.5% to 0.9% a year in perimenopausal
women [15-18], to above 1% after menopause [17,18]
after which the decline remains about 1% [14,19,20].
Other studies suggest after midlife there is an age-
related yearly loss of bone in both sexes of 1% [21]
which is accelerated to 2% for up to 14 years in women
around the age of menopause [22]. In men, a small loss
is detected in 40-year olds [14] that increases to a ~0.8%
per year into old age [14,19-21]. More recently, another
review has suggested that women will lose 35% to 39%,
men 17%-19%, of lifetime bone loss after achieving peak
bone mass at ages 30-40 years [23], changes that are
consistent with the previously cited studies. Additionally,
and perhaps an even more conservative estimate, com-
parisons were also made using ±0%/yr for all subjects in
both groups and sub-groups.
To evaluate safety, daily tracking self-reports, the 43-
item blood chemistry panel, and the 50-item Quality of
Life inventory [24] shown in Tables 2 and 3 were admi-
nistered to all study participants at baseline and at the
end of six months.
Compliance
To obtain a compliance rating, the research technician
who had the most frequent contact with subjects rated
the subjects’ compliance with the protocol using a 5-
point scale with “5” indicating “highly compliant” and
“1” indicating “not at all compliant” with the protocol.
This judgment was based on the subject’sr e p o r to ft h e
amount of product he/her consumed, the number of
steps reported on pedometer usage, whether or not they
had acquired any information from the health literacy
component, and her evaluation of the reliability of the
subject’s self-reported data based on her contact with
the subject over the 6-month study period. Upon com-
pletion of the technician’s ratings, one of the investiga-
tors (GRK) reviewed the data from the subjects’ daily
tracking forms and post-study anonymous question-
naires and compared it to the previous ratings. Finally,
joint subjective evaluation of the subjects’ overall com-
pliance was made. Less than 10% of the technicians’ rat-
ings were changed as a function of this joint review.
When making these ratings, both the technician and the
investigator were blinded with respect to the subject’s
BMD measurements.
Statistical Methods
To address concerns of bias in industry-sponsored
research, we provided an independent academic statisti-
cian who conducted all statistical analyses. He served as
the Principal Investigator, had full access to all study
data and source documents, and took responsibility for
the integrity of the data and the accuracy of the data
analysis.
Continuously distributed data were summarized with
the mean and standard deviation, and binary outcomes
were summarized with counts and percents. AC-1 and
AC-2 were contrasted on MAPC with analyses of covar-
iance with adjustment for age and sex. Group contrasts
Table 2 Comparison of Baseline Demographics
AlgaeCal 1 n = 125 AlgaeCal 2 n = 51
Demographic Mean ± SD Mean ± SD P-Value
Females 86.4% 78.4% 0.341
Age (years) 55.2 ± 11.2 56.7 ± 13.2 0.463
Weight (lbs) 153.6 ± 38.8 167.7 ± 55.0 0.709
% Body Fat 39.9% ±10.0% 35.9% ±10.2% 0.591
Fat Mass 63.0 ± 26.6 63.5 ± 38.3 0.938
Fat Free Mass 97.8 ± 21.1 104.2 ±23.9 0.082
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son’s chi-square. All statistical testing was 2-sided with
a significance level of 5%. SAS Version 9.1.3 for Win-
dows (SAS Institute, Cary, North Carolina) was used
throughout.
Results
As shown in Table 2, there were no significant differ-
ences between the groups in baseline BMD or in base-
line variables related to BMD, nor were there any
differences within these variables between subjects who
Table 3 Changes in blood chemistries in 126 subjects with study groups AlgaeCal 1and 2 Combined
Chemistry Normal Range Baseline Mean Ending Mean Change P-Values
TRIGLYCERIDES <150 mg/dL 111.4 114.7 3.26 0.395
CHOLESTEROL, TOTAL 125-200 mg/dL 193.3 196.7 3.38 0.171
HDL CHOLESTEROL > or = 40 mg/dL 58.2 58.8 0.59 0.388
LDL CHOLESTEROL <130 mg/dL 112.8 114.9 2.13 0.354
CHOL/HDLC RATIO < or = 5.0 3.5 3.6 0.02 0.705
GLUCOSE 65-95 mg/dL 96.9 95.8 -1.12 0.558
UREA NITROGEN (BUN) 7-25 mg/dl 14.4 14.8 0.44 0.163
CREATININE 0.50-1.20 mg/dL 0.86 0.88 0.02 0.002
BUN/CREATININE RATIO 6-22 17.1 17.1 -0.05 0.896
SODIUM 135-146 mmol/L 140.0 140.2 0.13 0.476
POTASSIUM 3.5-5.3 mmol/L 4.3 4.4 0.02 0.502
CHLORIDE 98-110 mmol/L 105.0 104.7 -0.29 0.001
CARBON DIOXIDE 21-33 mmol/L 24.4 25.1 0.79 0.132
CALCIUM 8.6-10.2 mg/dL 9.38 9.53 0.15 0.000
PROTEIN, TOTAL 6.2-8.3 g/dL 7.0 7.0 -0.02 0.586
ALBUMIN 3.6-5.1 g/dL 4.3 4.3 0.02 0.311
GLOBULIN 2.2-3.9 g/dL 2.7 2.7 -0.04 0.080
ALBUMIN/GLOBULIN RATIO 1.0-2.1 mg/dL 1.6 1.7 0.03 0.032
BILIRUBIN, TOTAL 0.2-1.2 mg/dL 0.6 0.6 -0.02 0.392
ALKALINE PHOSPHATASE 33-115 U/L 68.7 69.3 0.64 0.629
AST 10-35 U/L 20.7 18.5 -2.21 0.005
ALT 6-40 U/L 20.4 18.8 -1.61 0.163
WHITE BLOOD CELL COUNT 3.8-10.8 Thousand/uL 5.9 5.9 0.08 0.475
RED BLOOD CELL COUNT 3.80-5.10 Million/uL 4.5 4.5 -0.01 0.706
HEMOBLOBIN 11.7-15.5 g/dL 13.6 13.6 0.01 0.719
HEMATOCRIT 35.0-45.0% 40.4 40.5 0.11 0.467
MCV 80.0-100.0 fL 90.5 90.9 0.39 0.024
MCH 27.0-33.0 pg 33.7 33.6 -0.07 0.254
MCHC 32.0-36.0 g/dL 30.5 30.6 0.06 0.266
RDW 11.0-15.0% 13.8 13.7 -0.11 0.106
PLATELET COUNT 140-400 Thousand/uL 249.4 247.4 -2.05 0.339
ABSOLUTE NEUTROPHILS 1500-7800 cells/uL 3,460 3,534 74.0 0.442
ABSOLUTE LYMPHOCYTES 850-3900 cells/uL 1,858 1,821 -37.0 0.231
ABSOLUTE MONOCYTES 200-950 cells/uL 373.6 390.3 16.8 0.050
ABSOLUTE EOSINOPHILS 15-500 cells/uL 146.8 168.8 22.0 0.014
ABSOLUTE BASOPHILS 0-200 cells/uL 25.5 25.9 0.35 0.795
NEUTROPHILS 55-70% 58.0% 58.5% 0.01 0.482
LYMPHOCYTES 20-40% 32.3% 31.5% -0.01 0.119
MONOCYTES 2-8% 6.7% 6.8% 0.00 0.498
EOSINOPHILS 1-4% 2.6% 2.9% 0.00 0.033
BASOPHILS 0.5-1.0% 0.5% 0.4% 0.00 0.678
TSH W/REFLEX TO FT4 0.40-4.50 mIU/L 5.9 9.0 3.10 0.175
CARDIO CRP* 3.9 4.8 0.90 0.868
* <1.0 = Low Cardiovascular Risk, 1.0-3.0 = Average Risk, 3.1-10.0 High Risk, > 10.0 = Repeat test.
Michalek et al. Nutrition Journal 2011, 10:32
http://www.nutritionj.com/content/10/1/32
Page 5 of 10chose not to enroll and those who completed PP, or
between those who enrolled, but dropped, as compared
to those who completed PP.
Figure 2 shows bar-graphed representations of
expected and actual MAPC in BMD for both study
groups, compliant and partially-compliant sub-groups,
and over-expected changes in the two study groups. The
MAPC in BMD:
▪ minus the expected MAPC was greater than zero
in AC-1 [1.15% (3.62), p <0 . 0 0 1 ]a n di nA C - 2
[2.79% (3.57), p < 0.001];
▪ increased from baseline in AC-2, [2.18% (3.58), p <
0.001], but not in AC-1, [0.48% (3.64), p = 0.14];
▪ from baseline was greater in AC-2 [2.18% (3.58),
than in AC-1 [0.48% (3.64), p = 0.005);
▪ was greater in compliant subjects than in partially
compliant subjects in AC-1 [2.27% (3.62) vs. -1.02%
(2.92), p < 0.001], and in AC-2 [3.72% (3.96) vs.
0.82% (2.58), p = 0.003];
▪ of 3.72% in compliant subjects in AC-2 was greater
than in the 2.27% increase in AC-1, but this differ-
ence failed to reach statistical significance (p = 0.12);
▪ among partially compliant subjects, the 0.82%
increase in AC-2 was significantly greater than the
-1.02% decrease in AC-1 (p = 0.005);
▪ among compliant subjects the over-expected
increase in AC-2 [4.30% (3.98)] was greater than
AC-1 [2.27% (3.62)], but this difference failed to
reach statistical significance (p = 0.12).
With regard to the measures of safety, there were no
significant differences in blood chemistries between the
two study groups at baseline or end-of-study. Therefore,
their data were combined and are shown in Table 3.
Although the baseline/ending changes in 6 of the 43
blood chemistries were statistically significant, in no
instance did the average change exceed normal ranges.
Thus, changes within normal ranges were considered
clinically insignificant. With regard to the QOL, there
were no significant baseline/ending changes in any of
the 50 items or in the total scale scores, as shown in
Table 4.
Discussion
This CER study was initially designed to compare
changes in BMD in a bone health plan that incorporated
the three components recommended in the SG’s “call to
action” (improved nutrition, increased health literacy,
and increased physical activity) with expected changes
in BMD as reported in non-intervention studies. In
addition to the primary outcome measure of changes in
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1  vs.  3 p=0.29
1  vs.  4 p<0.001
6  vs.  7 p<0.001
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Figure 2 Comparisons of mean annualized changes in bone mineral density from baseline in two groups, AlgaeCal 1 and AlgaeCal 2,
following the same bone-health plan, but with different versions of an enhanced plant-sourced form of calcium. AlgaeCal 1: 1 =
Expected Changes (adjusted for age & gender), 2 = Change from Baseline, 3 = Changes in Partially Compliant Subjects, 4 = Changes in
Compliant Subjects, 5 = Changes in Compliant Subjects Over-expected (1 + 4). AlgaeCal 2: 6 = Expected Changes (adjusted for age & gender), 7
= Change from Baseline, 8 = Changes in Partially Compliant Subjects, 9 = Changes in Compliant Subjects, 10 = Changes in Compliant Subjects
Over-expected (6 + 10).
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effects, and effects of compliance were also examined.
Upon completion of this initial study, a second study
was commissioned to compare the effects of following
the same bone-health plan, but with a different version
of the calcium bone-health supplement.
Although the sequential design, as opposed to an
RCT, posed difficulties in interpreting the data, the
results suggests that following the AC-2 plan led to sig-
nificantly greater increases in BMD than expected and
than the AC-1 plan. This conclusion is based on
between-group comparisons of the MAPC in: (A) AC-1
as compared to (B) AC-2, an untreated age- and gen-
der-adjusted expected change control group, and (C)
between compliant sub-groups in AC-1 and AC-2. Sup-
port for The Plan’s efficacy is also provided by the
within-group comparisons of changes from baseline and
between compliant and partially-compliant sub-groups,
a finding consistent with an exhaustive meta analysis of
23 trials (n = 41,419) of the effects of supplementation
on BMD [25]. These researchers concluded that poor
compliance is the major obstacle to obtaining full
Table 4 Changes in Blood Chemistries for 126 Subjects completing the test battery at baseline and end-of-study
RATING SCALE Baseline
Mean
Change
from
Baseline
Repeated
Measures P
Levels
RATING SCALE Baseline
Mean
Change
from
Baseline
Repeated
Measures
P Levels
0 = Not a problem 1 = A
MINOR problem
0 = Not a problem 1 = A
MINOR problem
2 = A MAJOR problem
3 = A SEVERE problem
2 = A MAJOR problem
3 = A SEVERE problem
Average Total Score 0.289 -0.001 0.958 25 Lupus* 0.031 0.000 N/A
01 Headaches 0.328 0.023 0.670 26 Irregular heartbeat 0.185 -0.040 0.277
02 Irritable bowel syndrome 0.215 0.059 0.171 27 Shortness of breath 0.131 -0.001 1.000
03 Arthritis 0.512 -0.015 0.725 28 Constipation or diarrhea 0.397 0.046 0.448
04 Premenstrual syndrome 0.156 0.025 0.435 29 Stomach gas or
indigestion
0.411 -0.003 0.774
05 Recurring sinus
infections
0.260 -0.038 0.355 30 Feeling weak 0.290 0.002 1.000
06 Tension fatigue
syndrome
0.305 0.067 0.319 31 Eating too rapidly 0.346 -0.056 0.150
07 Recurrent anxiety 0.285 -0.010 0.854 32 Eating after being full 0.359 -0.051 0.251
08 Recurrent depression 0.275 0.000 1.000 33 Embarrassed about
overeating
0.122 0.046 0.202
09 Insomnia 0.481 0.015 0.815 34 Depressed over eating
habits
0.160 0.023 0.614
10 Low self esteem 0.260 -0.046 0.305 35 Depressed about my
weight
0.374 0.008 0.887
11 Binge eating 0.176 0.092 0.064 36 Difficult to stop eating 0.214 0.002 1.000
12 Chronic tension 0.321 0.008 0.889 37 Worrying about the
future
0.450 -0.050 0.624
13 Lack of energy 0.669 0.003 1.000 38 Unable to concentrate 0.481 -0.112 0.058
14 Food allergies 0.260 -0.044 0.258 39 Forgetfulness 0.588 -0.023 0.707
15 Feeling under stress 0.809 -0.008 0.916 40 Bad temper or quick to
anger
0.244 -0.015 0.725
16 Cancer 0.031 0.008 0.656 41 Indigestion 0.214 -0.015 0.696
17 Prostate problems 0.057 -0.015 0.158 42 Diabetes 0.130 -0.031 0.250
18 Overeating 0.385 0.035 0.663 43 Vomiting 0.000 0.000 N/A
19 Stomach pain 0.099 0.084 0.048 44 Heartburn 0.208 0.008 0.858
20 Back pain 0.649 0.015 0.797 45 Esophageal reflux 0.214 -0.037 0.299
21 Pain in arms, legs or
joints
0.656 -0.008 0.887 46 Control over my
appetite
0.305 0.000 1.000
22 Menstrual pain or
problems
0.160 -0.003 1.000 47 Ability to relax 0.443 0.015 0.794
23 Chest pain 0.085 -0.016 0.529 48 Heart disease 0.115 -0.023 0.319
24 Dizziness 0.154 0.022 0.566 49 Fibromyalgia 0.096 -0.013 0.259
*At baseline, only one subject recorded a rating for Lupus and no one, including this subject, recorded any ending rating of Lupus precluding the calculation of
a P value and making the rating irrelevant. It is our view that most likely the baseline rating was an error.
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Page 7 of 10benefit of supplementation and that compliant subjects
doubled their risk reduction, suggesting high compliance
is needed to demonstrate the therapeutic efficacy of sup-
plementation. Support for the safety of the AC-1 Plan is
provided by the absence of adverse events or changes
from baseline in the QOL, daily tracking reports and the
43-chemistry blood panel.
One apparent difficulty in interpreting the findings is
the loss of 1.02% of MAPC in the partially-compliant
sub-group following the AC-1 plan (bar-graph #3,
Figure 2). Although the bar-graph suggests that this
sub-group lost more BMD than expected (bar-graph
#1), the difference was not statistically significant (p =
0.29) suggesting that changes in the AC-1 plan were no
different than expected. The most parsimonious expla-
nation for the absence of any change in BMD for the
partially compliant sub-group taking AC-1 is that this
bone-health plan had no effect on BMD when subjects
only partially adhered to The Plan, but did facilitate
change among more compliant subjects. Conversely,
when following The Plan with AC-2, even the partially-
compliant subjects increased their BMD and subjects
classified as compliant had greater increases than par-
tially-compliant subjects taking AC-2. Thus, the data
suggest that there may be a threshold below which no
changes in BMD occur and above which changes do
occur. The threshold appears to be between partially
compliant and compliant subjects taking AC-1.
Study Weaknesses and Mitigating Factors
Although these data support a comparative effectiveness
interpretation of the superiority of the AC-2 plan,
absent a placebo-controlled arm, one could conclude
that the increased MAPC from baseline and over-
expected was attributable to using a sequential design
resulting in unequal subject groups, a placebo effect or
invalid expected change data. With regard to the equiva-
lence of the groups, while it was impossible to rule out
all potentially confounding variables, increased confi-
dence in the similarity of the two groups was obtained
from comparisons of a number of baseline measures
associated with changes in BMD. There were no statisti-
cal differences between the groups on age, gender and
B M D .N o rw e r et h e r ea n ys i g n i f i c a n tb a s e l i n ea n dp r e -
post-study differences on body composition variables
that have been reported to affect BMD [26] (weight,
lean mass, % fat, and BMI). Additionally, no differences
were found between the groups on the QOL, lipid
panel, C-reactive protein, serum calcium or thyroid
levels. Of the 43 blood chemistries measured in both
groups, only two (platelets and alkaline phosphatase)
differed between the groups (p < 0.01). In neither group
were there differences between volunteers and non-
volunteers, nor between those subjects who completed
versus those who dropped out. Taken together, these
similarities provide considerable evidence that the two
groups were reasonably equivalent at baseline.
With regard to placebo effects, it seems implausible to
suggest that the reported changes in BMD were the
result of placebo effects, particularly in view of a num-
ber of studies comparing changes in BMD that showed
virtually no change in the placebo arms. For example,
three randomized double-blinded placebo-controlled
studies measuring the effects of strontium ranelate
[27-29] found a progressive and linear decrease in BMD
in each of three years with a 1% decline after 12
months–a decline virtually identical to the two age-gen-
der adjusted expected changes used in this study.
In contrast to the absence of studies on placebo
effects on BMD, a number of studies have suggested
that consumption of the multiple nutrients in AC-1 and
AC-2 could facilitate increases in BMD. Although we
could find no studies on the effects on BMD of stron-
tium citrate used in both formulas (as opposed to the
plethora of studies on strontium ranelate), considerable
evidence is available on the bone-health effects of the
other nutrients in the AC formula–supplemental mag-
nesium, vitamin K-2, [30,31] and calcium and Vitamin
D3 [32]. Vitamin C has also been reported as an essen-
tial nutrient for collagen formation and normal bone
development, particularly in older men and women
[33,34]. Further support for the increased BMD may be
because AC is a plant-sourced supplement and some
studies have suggested plant-sourced minerals may be
more easily absorbed than non-plant-sourced calcium
and minerals [35-39] suggesting that the body was able
to use less than 10 percent of the synthetic minerals
contained in the most popular brands of multivitamins
as opposed to over 80 percent of minerals derived from
plant sources. Other studies have also reported positive
associations between fruit and vegetable consumption
and BMD in elderly adults [40,41], adolescents [42] and
children [43].
With regard to the validity of the expected change
data, the studies cited above suggest that the annual
expected decrease in BMD is closer to -1.0% as opposed
to the -0.67% and -0.63% used in this study. Addition-
ally, although some studies have reported that supple-
mentation with vitamin D3 and calcium had no effect
on the decline of age-related BMD [44,45], the general
consensus is that supplementation does result in a lower
rate of annual bone loss [26]. These data would suggest
that even with supplementation, the expected annualized
change in BMD is between the -1.0% and -0.2%, particu-
larly since there is no compelling evidence that supple-
mentation leads to an increase in BMD.
No attempt was made to partition the effects of the
three components of The Plan, since the goal of the
Michalek et al. Nutrition Journal 2011, 10:32
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Page 8 of 10study was to examine the effectiveness of the plans, not
the individual components int h ep l a n s .H o w e v e r ,t h e
increased MAPC found in AC-2, as compared to AC-1,
suggests that the modifications made to the nutritional
profile of AC-2, while holding all other components
constant, provided additional benefits over and above
the benefits provided by the other components of The
Plan.
Study strengths
One strength of this study is that it was conducted in
“real world” conditions which maximized the inclusion
criteria and minimized the exclusion criteria by enrol-
ling adults of all age, gender and ethnicity, which
increases confidence that the results could be general-
ized to populations that are most likely to use the pro-
duct. Other strengths include the well established
reliability and validity of DXA measurements of BMD,
the analysis and absence of evidence of volunteer and
attrition biases, baseline similarities between the two
treatment groups, consistency of the expected within-
groups differences in compliance, and the experience
levels of the testing and research technicians.
With regard to safety, the use of pre- and post-study
QOL inventories and independently-measured blood
chemistries completed by both groups at baseline and
end-of-study contribute to the safety of the study, as
does the absence of reported adverse effects on these
measures and on the daily tracking forms.
Conclusions
Compared to an initial formulation, using the revised
AC nutritional supplement, AC-2, with additional levels
and types of nutrients, while holding all other compo-
nents of The Plan constant, was associated with signifi-
cantly greater increases in mean bone density. These
increases were significantly greater than baseline BMD
a n da sc o m p a r e dt oa g e -a n dg e n d e r - a d j u s t e de x p e c t e d
changes. No evidence was found of adverse side effects,
volunteer bias, drop-out bias, or differences between the
age and gender of the participant. Additional support
for the efficacy of AC-2 was found by significant differ-
ences between compliant and partially compliant partici-
pants, suggesting a does-related effect. Notwithstanding
the absence of an RCT, these findings warrant further
study in view of the unusual increases in BMD in both
study groups. It is a marked departure from previous
studies in which the decline in BMD has been found to
be slowed or, at best, maintained.
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